Physician profile
Abdul Basit
NPI 1578555769
$2,014.16
in general payments reported to CMS, 2019-2025
30 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.35 · 2021: $38.61 · 2024: $708 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.26 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $285.67 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $200.24 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $160.07 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $146.25 | 2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $125.10 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $114.43 | 2024-2025 | Winrevair |
| United Therapeutics Corporation | $108.11 | 2024-2025 | Tyvaso, Remodulin, Orenitram |
| Baxter Healthcare | $102.04 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $82.24 | 2024-2025 | Glassia |
| Inspire Medical Systems, INC. | $71.57 | 2025 | Inspire |
| Harmony Biosciences LLC | $57.44 | 2025 | |
| Genzyme Corporation | $55.85 | 2024-2025 | |
| Insmed, INC. | $51.88 | 2024-2025 | Arikayce |
| Genentech USA, INC. | $44.20 | 2024-2025 | Xolair |
| Axsome Therapeutics, INC. | $43.52 | 2024-2025 | Sunosi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.40 | 2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $38.50 | 2024-2025 | |
| Abbott Laboratories | $38.22 | 2025 | Agilis Hispro |
| Viatris Specialty LLC | $37.83 | 2025 | Yupelri |
| Verona Pharma, INC. | $26.10 | 2025 | Ohtuvayre |
| Allergan, INC. | $25.99 | 2019 | |
| Abbvie INC. | $22.28 | 2021 | |
| Viiv Healthcare Company | $22.19 | 2025 | Dovato |
| Grifols USA, LLC | $21.43 | 2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $21.37 | 2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2024 | Ofev |
| Advanced Respiratory, INC | $16.33 | 2021 | |
| Phadia US INC. | $13.76 | 2024 | Immunocap |
| Actelion Pharmaceuticals US, INC. | $13.39 | 2024 | Uptravi, Opsumit |
| Mission Pharmacal Company | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Basit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.